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Infections of Exophiala spp. and Fusarium spp. are often chronic and recalcitrant.
Systemic disseminations, whichmostly occur in immunocompromised patients, are often
refractory to available antifungal therapies. The conserved target of rapamycin (TOR)
orchestrates cell growth and proliferation in response to nutrients and growth factors,
which are important for pathogenicity and virulence. INK128 is a second-generation
ATP-competitive TOR inhibitor, which binds the TOR catalytic domain and selectively
inhibits TOR. In the present study, we investigated the in vitro activities of INK128 alone
and the interactions of INK128 with conventional antifungal drugs including itraconazole,
voriconazole, posaconazole, and amphotericin B against 18 strains of Exophiala spp.
and 10 strains of Fusarium spp. via broth microdilution checkerboard technique system
adapted from Clinical and Laboratory Standards Institute broth microdilution method
M38-A2. INK128 alone was inactive against all isolates tested. However, favorable
synergistic effects between INK128 and voriconazole were observed in 61% Exophiala
strains and 60% Fusarium strains, despite Fusarium strains exhibited high MIC values
(4–8µg/ml) against voriconazole. In addition, synergistic effects of INK128/itraconazole
were shown in 33% Exophiala strains and 30% Fusarium strains, while synergy of
INK128/posaconazole were observed in 28% Exophiala strains and 30% Fusarium
strains. The effective working ranges of INK128 were 0.125–2µg/ml and 1–4µg/ml
against Exophiala isolates and Fusarium isolates, respectively. No synergistic effect
was observed when INK128 was combined with amphotericin B. No antagonism was
observed in all combinations. In conclusion, INK128 could enhance the in vitro antifungal
activity of voriconazole, itraconazole and posaconazole against Exophiala spp. and
Fusarium spp., suggesting that azoles, especially voriconazole, combined with TOR
kinase inhibitor might provide a potential strategy to the treatment of Exophiala and
Fusarium infections. However, further investigations are warranted to elucidate the
underlying mechanism and to determine possible reliable and safe application in clinical
practice.
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INTRODUCTION
Exophiala spp. and Fusarium spp. are both increasingly
recognized opportunistic pathogen causing cutaneous,
subcutaneous and serious invasive infections, especially in
immunocompromised and debilitated individuals (Li et al., 2011;
Guarro, 2013). Human infection usually occurs as a result of
inoculation of the organism through the body surface causing
local infection. E. dermatitidis is one of the most common cause
of chromoblastomycosis (Li et al., 2011), while Fusarium spp.
causes keratitis and onychomycosis, or locally invasive infections
(Guarro, 2013). However, disease in immunocompromised
patients often manifests with systemic disseminated fungemia,
whose prevalence is effectively growing (Li et al., 2011; Guarro,
2013). E. dermatitidis is the leading cause of severe neurotropic
phaeohyphomycosis (Li et al., 2011), while fusariosis is, after
aspergillosis, the second most common mold infection in
humans, among which F. solani species complex and F.
oxysporum species complex are responsible for approximately
80% of the cases (Guarro, 2013).
Prompt antifungal treatment is crucial to prevent life-
threatening disease. However, fusariosis is mostly refractory to
available treatment, with a high mortality rate for systemic
disseminations, which is in accordance with the poor in vitro
activities of available antifungal drugs against Fusarium spp.
(Guarro, 2013). In addition, success rate for Exophiala spp.
infection was only 40–70% despite most antifungal drugs showed
favorable in vitro activities (Revankar and Sutton, 2010; Kondori
et al., 2011; Patel et al., 2013). Optimal treatment remains
elusive. Therefore, novel therapeutic strategies are desperately
needed.
The target of rapamycin (TOR), which is a conserved
serine/threonine kinase in eukaryotes from yeast to humans
and orchestrates cell growth and proliferation in response
to nutrients and growth factors, is a promising target
for the development of novel antifungal strategy (Crespo
and Hall, 2002). It has been demonstrated that the TOR
pathway regulates cellular responses to nutrients in yeast cells,
including proliferation, translation, transcription, autophagy,
ribosome biogenesis, lipid homeostasis, morphogenesis and
cellular aggregation, which have important implications for
pathogenicity and virulence (Crespo and Hall, 2002; Madeira
et al., 2015). Therefore, the TOR signaling cascade is an excellent
target for the development of broad-spectrum antifungal
agents. INK128 is a second-generation ATP-competitive TOR
inhibitor, which binds the TOR catalytic domain and selectively
inhibits TOR (Hsieh et al., 2012). Previous study revealed
synergistic effects between INK128 and itraconazole (ITC),
voriconazole (VRC), posaconazole (POS) against Aspergillus
spp. (Gao et al., 2016). Thus, it is reasonable to speculate
that INK128 might also have some antifungal activity and
interactions with antifungals against Exophiala spp. and
Fusarium spp.
The aim of this study was to evaluate the effects of INK128
alone and combined with antifungal agents against Exophiala
spp. and Fusarium spp.
MATERIALS AND METHODS
Fungal Strains
A total of 18 strains of E. dermatitidis and 10 strains of Fusarium
spp. (7 strains of F. solani, and 3 strains of F. oxysporum) were
studied. All strains were clinical isolates. Fungal identification
was determined by microscopic morphology and by molecular
sequencing of the internal transcribed spacer (ITS) ribosomal
DNA (rDNA), as required.Candida parapsilosisATCC 22019 was
included to ensure quality control.
Antifungals and Chemical Agents
All tested drugs including INK128 (purity ≥ 99%), ITC (purity
≥ 99%), VRC (purity ≥ 99%), POS (purity ≥ 99%), and
amphotericin B (AMB; purity ≥ 80%) were purchased in
powder form from Selleck Chemicals, Houston, TX, USA
and prepared as outlined in the Clinical and Laboratory
Standards Institute (CLSI) broth microdilution method M38-A2
(Clinical and Laboratory Standards Institute, 2008). The working
concentration ranges of tested drugs were all 0.03–16µg/ml.
Inoculum Preparation
Conidia harvested from cultures grown for 7 days on Sabouraud
dextrose agar (SDA) were suspended in sterile distilled water
containing 0.03% Triton and diluted to a concentration of 1–5×
106 spores/ml, which were than diluted 100 times in RPMI-
1640 to achieve a 2-fold suspension more concentrated than the
density needed or to approximately 1–5× 104 spores/ml (Clinical
and Laboratory Standards Institute, 2008).
In vitro Antifungal Activity of Individual
Tested Agents
The individual minimal inhibitory concentrations (MICs) of
INK128, ITC, VRC, POS and AMB were determined according
to M38-A2 method (Clinical and Laboratory Standards Institute,
2008). The 96-well plate was inoculated with 100µl of the
inoculum suspension prepared and 100µl of the serial diluent
of tested drugs. Interpretation of results was performed after
incubation at 35◦C for 48 h for Fusarium spp. and 72 h
for Exophiala spp., respectively. All tests were performed in
triplicate.
In vitro Interactions of INK128 and
Antifungals Agents
The interactions between INK128 and antifungal agents against
all strains were tested via the microdilution chequerboard
technique, adapted from the CLSI M38-A2 microdilution
method (Clinical and Laboratory Standards Institute, 2008).
As described, a 50 µl of INK128 with serial dilutions were
inoculated in horizontal direction and another 50µl of azoles
or AMB with serial dilutions were inoculated in vertical
direction on the 96-well plate, which contained 100µl prepared
inoculum suspension. Interpretation of results was performed
after incubation at 35◦C for 48 h for Fusarium spp. and 72 h for
Exophiala spp., respectively. Drug combination interaction was
classified on the basis of the fractional inhibitory concentration
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index (FICI). The FICI as calculated by the formula: FICI =
(Ac/Aa) + (Bc/Ba), where Ac and Bc are the MICs of antifungal
drugs in combination, and Aa and Ba are the MICs of antifungal
drugs A and B alone (Tobudic et al., 2010). All tests were
performed in triplicate.
Interpretation of Results
The MICs were determined as the lowest concentration resulting
in complete inhibition of growth (Clinical and Laboratory
Standards Institute, 2008). The interaction of INK128 with
azoles, or AMB referred to the fractional inhibitory concentration
index (FICI), which was classified as follows: FICI of ≤0.5,
synergy; FICI of >0.5 to ≤4, no interaction (indifference); FICI
of >4, antagonism (Odds, 2003).
RESULTS
In vitro Antifungal Activity of Individual
Tested Agent
The MIC ranges of individual tested drugs against E. dermatitidis
isolates were >16 µg/ml for INK128, 0.5–1µg/ml for ITC, 0.25–
0.5µg/ml for VRC, 0.25–1µg/ml for POS, and 0.5–1µg/ml for
AMB, respectively (Table 1). The MIC ranges against Fusarium
spp. are>16µg/ml for INK128 and ITC, 4–8µg/ml for VRC and
POS, and 2–4µg/ml for AMB, respectively (Table 2). INK128
individually did not exhibit any significant antifungal activity
against all tested strains of Fusarium spp. and Exophiala spp.
In vitro Interactions between INK128 and
Antifungal Agents
When INK128 was combined with VRC, the MICs of INK128
and VRC against Exophiala spp. decreased to 0.125–2µg/ml
and 0.03–0.25µg/ml, respectively, demonstrating favorable
synergistic effects against 11 (61%) strains of E. dermatitidis
(Table 1). Similarly, this INK128/VRC combination also showed
favorable synergism against 6 (60%) strains of Fusarium isolates
(Table 2), where the MIC ranges of INK128 and VRC decreased
to 1–2µg/ml and 1–4µg/ml, respectively. The effective working
ranges of INK128 in this combination were 0.125–2µg/ml and
1-2µg/ml against Exophiala spp. and Fusarium spp., respectively.
When INK128 was combined with POS, the MIC ranges
of INK128 and POS against Exophiala spp. decreased to
0.125–1µg/ml and 0.125–0.5µg/ml, respectively (Table 1). The
MIC ranges of INK128 and POS against Fusarium spp.
decreased to 2–8µg/ml and 1–4µg/ml, respectively (Table 2).
The INK128/POS combination revealed synergistic effects
against only 5 (28%) strains of Exophiala spp. and 3(30%)
strains of Fusarium spp. (Tables 1, 2). The effective working
ranges of INK128 in INK128/POS combination were 0.125–
0.25µg/ml and 2µg/ml against Exophiala spp. and Fusarium
spp., respectively.
When INK128 was combined with ITC, the MIC ranges
of INK128 and ITC against Exophiala spp. decreased to
0.125–2µg/ml and 0.06–1µg/ml, respectively. The MIC ranges
of INK128 and ITC against Fusarium spp. decreased to
4–8µg/ml and 4–16µg/ml, respectively. Synergistic effects of
the INK128/ITC combination were only observed in only 6
(33%) strains of Exophiala spp. and 3(30%) strains of Fusarium
spp. (Tables 1, 2). The effective working ranges of INK128
in INK128/ITC combination were 0.25–2µg/ml and 4µg/ml
against Exophiala spp. and Fusarium spp., respectively.
No synergistic effect was observed when INK128 was
combined with AMB. No antagonism was observed in these
combinations.
DISCUSSION
TOR kinase is the central element of TOR signaling pathway,
which has been widely investigated for years since its discovery
and has been recognized as a central controller of cell growth
in eukaryotes (Crespo and Hall, 2002). The pharmaceutical
potential of rapamycin, the classical allosteric inhibitor of TOR,
was originally discovered in a screen for novel antifungal
agents. Rapamycin was found to exhibit potent antifungal effects
against a variety of species including Candida spp., Cryptococcus
spp., Aspergillus spp., Fusarium spp., Penicillium spp., and
dermtophytes (Rohde and Cardenas, 2004). However, rapamycin
failed to be used as an antifungal due to its even more potent
immunosuppressive property.
INK128, a highly potent, orally active TOR kinase inhibitor,
was originally developed for cancer treatment (Hsieh et al.,
2012). It has been demonstrated that oral administration of
INK128 in mice has high absorption and bioavailability, with
doses of 3 mg/kg giving a Cmax of 0.599µg/ml in plasma
(Hsieh et al., 2012). Moreover, previous study has shown that
INK128 did not inhibit in vitro peripheral blood lymphocytes
proliferation at concentrations of up to 1µM (0.31µg/ml),
and daily administration of INK128 at a dose up to 5mg/kg
in humanized mice over a 2-week period showed no obvious
toxicity (Heredia et al., 2015), suggesting that INK128 is not as
immunosuppressive as rapamycin.
Previously, we have demonstrated that INK128 exhibited
synergistic effects with ITC (65%), VRC (61%), POS (50%)
against Aspergillus spp. (Gao et al., 2016). In the present study,
we investigated the in vitro antifungal activity of INK128 alone
and combined with antifungal agents against Exophiala spp.
and Fusarium spp. The results revealed that INK128 alone was
inactive against all strains tested, as was demonstrated against
Aspergillus isolates (Gao et al., 2016). Nevertheless, synergistic
activities between INK128 and VRC (61%), ITC (33%), POS
(28%) were observed in Exophiala spp. Although, the MIC
values of ITC, VRC and POS against Fusarium strains were
much higher that those against Exophiala spp., synergistic
effects between INK128 and VRC (60%), ITC(30%), POS
(30%) against Fusarium isolates were comparable to those
of Exophiala spp. The effective working ranges of INK128
were 0.125–2 µg/ml and 1–4 µg/ml against Exophiala spp.
and Fusarium spp., respectively. No interaction between
INK128 and AMB was observed. Moreover, no antagonism
was observed.
Synergistic effects between INK128 and ITC or POS against
Exophiala spp. and Fusarium spp. were less frequent than those
observed in Aspergillus spp. (Gao et al., 2016). However, synergy
between INK128 and VRC was comparable among Exophiala
spp., Fusarium spp., and previously tested Aspergillus spp. (Gao
et al., 2016), despite Fusarium spp. showed relatively poor
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TABLE 1 | MICs and FICIs results with combinations of INK128 with antifungal agents against E. dermatitidis.
Strain MICa (µg/ml) FICIb MICa (µg/ml) FICIb MICa (µg/ml) FICIb MICa (µg/ml) FICIb
INK128 ITC INK128/ITC VRC INK128/VRC POS INK128/POS AMB INK128/AMB
E. dermatitidis (1) >16 0.5 0.125/0.25 I 0.25 0.125/0.03 S 0.5 1/0.25 I 1 0.5/1 I
E. dermatitidis (2) >16 1 0.5/0.5 I 0.25 0.125/0.06 S 1 0.25/0.125 S 1 0.5/1 I
E. dermatitidis (3) >16 1 2/0.25 S 0.25 0.25/0.03 S 0.5 0.125/0.5 I 1 0.5/0.5 I
E. dermatitidis (4) >16 0.5 0.25/0.125 S 0.25 0.25/0.06 S 0.25 0.125/0.25 I 1 0.25/1 I
E. dermatitidis (5) >16 0.5 0.5/0.06 S 0.25 0.25/0.03 S 0.5 0.125/0.125 S 1 0.5/1 I
E. dermatitidis (6) >16 0.5 0.25/0.25 I 0.25 0.125/0.06 S 0.5 0.125/0.5 I 0.5 0.25/0.5 I
E.dermatitidis (7) >16 0.5 0.125/0.25 I 0.5 0.125/0.25 I 0.5 0.125/0.5 I 1 1/0.5 I
E.dermatitidis (8) >16 0.5 0.5/0.125 S 0.25 0.25/0.06 S 0.25 0.125/0.125 I 0.5 1/0.5 I
E.dermatitidis (9) >16 0.5 0.125/0.5 I 0.25 0.125/0.25 I 0.5 0.25/0.5 I 1 0.5/1 I
E.dermatitidis (10) >16 1 0.125/1 I 0.25 0.125/0.25 I 0.5 0.125/0.5 I 0.5 0.5/0.25 I
E. dermatitidis (11) >16 1 0.5/1 I 0.25 0.25/0.125 I 0.5 0.125/0.5 I 1 1/0.5 I
E. dermatitidis (12) >16 0.5 0.125/0.5 I 0.25 0.25/0.03 S 0.5 0.125/0.125 S 1 0.5/1 I
E. dermatitidis (13) >16 0.5 2/0.5 I 0.5 2/0.125 S 0.5 0.25/0.125 S 1 0.5/1 I
E. dermatitidis (14) >16 1 0.5/0.25 S 0.5 0.25/0.25 I 0.5 0.125/0.5 I 0.5 0.25/0.5 I
E. dermatitidis (15) >16 1 0.25/0.5 I 0.5 0.25/0.125 S 0.5 0.125/0.5 I 1 1/0.5 I
E. dermatitidis (16) >16 1 0.125/0.5 I 0.5 0.5/0.25 I 0.5 0.125/0.5 I 0.5 0.25/0.25 I
E. dermatitidis (17) >16 0.5 0.5/0.25 I 0.25 0.25/0.25 I 0.5 0.25/0.25 I 1 0.5/1 I
E. dermatitidis (18) >16 1 0.25/0.25 S 0.25 0.125/0.03 S 0.5 0.25/0.125 S 1 0.5/1 I
aThe MIC is the concentration achieving 100% growth inhibition.
bS, synergy (FICI of ≤ 0.5); I, no interaction (indifference) (0.5 < FICI ≤ 4).
TABLE 2 | MICs and FICIs results with combinations of INK128 with antifungal agents against Fusarium spp.
Strain MICa (µg/ml) FICIb MICa (µg/ml) FICIb MICa (µg/ml) FICIb MICa (µg/ml) FICIb
INK128 ITC INK128/ITC VRC INK128/VRC POS INK128/POS AMB INK128/AMB
F. solani (1) >16 >16 4/8 I 8 2/2 S 4 2/4 I 4 8/4 I
F. solani (2) >16 >16 4/8 I 4 2/2 I 4 2/2 I 2 8/2 I
F. solani (3) >16 >16 4/4 S 8 2/2 S 4 4/2 I 4 8/4 I
F. solani (4) >16 >16 4/8 I 8 1/2 S 4 8/4 I 4 8/4 I
F. solani (5) >16 >16 4/16 I 8 2/4 I 4 2/1 S 2 4/2 I
F. solani (6) >16 >16 8/16 I 8 2/2 S 4 2/4 I 4 4/2 I
F. solani (7) >16 >16 4/4 S 8 2/1 S 8 2/2 S 2 8/2 I
F. oxysporum (1) >16 >16 8/16 I 8 2/4 I 4 4/4 I 4 4/4 I
F. oxysporum (2) >16 >16 8/16 I 8 2/4 I 8 2/2 S 4 4/4 I
F. oxysporum (3) >16 >16 4/4 S 8 2/2 S 4 8/4 I 2 4/1 I
aThe MIC is the concentration achieving 100% growth inhibition.
bS, synergy (FICI of ≤ 0.5); I, no interaction (indifference) (0.5 < FICI ≤ 4).
antifungal susceptibility profile. It is important to note that even
with high MICs against VRC (4–8 µg/ml), synergy between
INK128 and VRC was observed in up to 60% Fusarium strains,
implicating that INK128 could enhance the in vitro susceptibility
of VRC-inactive Fusarium strains. The effective working ranges
of INK128 against Exophiala spp. were mostly within 0.125–
0.25 µg/ml, which could be achieved safely as mentioned above.
Compared to Exophiala spp., the working ranges of INK128
against Fusarium spp. were higher, which might associated with
the inherently high MICs of Fusarium spp. to most available
antifungal medications.
Previous studies have demonstrated synergistic interactions
between rapamycin and AMB (70%), ITC (50%), POS (40%)
against Mucorales (previously referred to as zygomycetes)
through brothmicrodilution checkerboard procedure (Dannaoui
et al., 2009). Futhermore, antagonism of rapamycin/ITC, and
indifference to significant antagonism of rapamycin/POS against
Mucorales (previously referred to as zygomycetes) have also been
reported (Dannaoui et al., 2009; Narreddy et al., 2010). However,
there was no interaction between INK128 and AMB against
tested Exophiala spp. and Fusarium spp. in the present study,
or Aspergillus spp. in the previous study (Gao et al., 2016). No
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antagonism between INK128 and POS or ITC was observed. The
explanation of the difference between INK128 and rapamycin
might lie in the different mechanism through which INK128
and rapamycin interact with TOR and antifungals, and different
response of tesed species against these antifungal drugs.
In summary, the present study extends previous findings in
the combination interactions between TOR inhibitors, especially
INK128, and conventional antifungals. INK128 could enhance
the in vitro antifungal activity of VRC, ITC, and POS against
Exophiala spp. and Fusarium spp. More importantly, the
inexistence of immunosuppression of INK128 suggests that
the combination of azoles with INK128 might provide a safe
alternative strategy to the treatment of Exophiala and Fusarium
infections. However, further investigations are warranted to
elucidate the underlying mechanism and to determine possible
reliable and safe application in clinical practice.
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